News
Pegylated Liposomal Irinotecan + 5-FU/LV in the Treatment of mPDAC in Czech Clinical Practice – Results from the VILP Registry
At last year's annual congress of the European Society for Medical Oncology (ESMO) and this year's 15th PragueONCO, results from the Czech VILP registry were presented. This registry collected data on patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with pegylated liposomal irinotecan (nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV). The efficacy and safety of nal-IRI + 5-FU/LV in patients with mPDAC after failure or intolerance to gemcitabine-based chemotherapy, as found in the randomized…
Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
The possibilities of biological therapy for severe forms of psoriasis are very broad today. Achieving...
How Does Artificial Intelligence Help in Drug Development?
In recent years, technologies leveraging artificial intelligence have transitioned from potentially…
Improvement in social functioning of patients with schizophrenia during treatment with lurasidone
A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A…
What to add to amlodipine when it alone is not enough for hypertension?
Treating hypertension is a daily task for not only general practitioners and cardiologists. Polish…
ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and…
Causes, Consequences, and Solutions to Weight Gain in Schizophrenia Treatment
The use of antipsychotics in the treatment of schizophrenia is often associated with the…
Current findings on the treatment of gestational diabetes and DM2 in pregnancy with metformin
Recent reviews have shown that metformin is a safe alternative to insulin in the treatment of…
Trastuzumab Deruxtecan in Patients with HER2+ Metastatic Breast Cancer
Last year, results of studies published in the Lancet journal demonstrated a significant clinical…
Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for…